fig3
![Glycogen synthase kinase 3β biology in bone and soft tissue sarcomas](https://image.oaes.cc/75464bb3-86d4-4087-aabd-d1cf45ea8fdc/3820.fig.3.jpg)
Figure 3. Therapeutic efficacy of GSK3β inhibitors (AR-A014418 and SB-216763) against human osteosarcoma cell orthograft tumors in the knee joints of mice[46] (left panels) and schematic representation of the hypothetical triple benefits of GSK3β inhibitors: anti-tumor effect, reduction of post-surgery tissue defect, and bone preservation (right panels). Dotted lines in the middle two panels indicate the area of orthograft tumors. GSK3β: glycogen synthase kinase 3β; DMSO: dimethyl sulfoxide (diluent for GSK3β inhibitors)